The contribution that the study of animal physiology makes to cardiovascular medicine can be said to originate from observations by Malpighi of Bologna in 1661, but recent attention to species variation in the control of the cardiovascular system (CVS) has allowed us to improve the predictive ability of experimental models of human disease. Historically, it has been practicable to examine the detail of regulatory biochemical and physiological controls only in experimental animals, but the implementation of noninvasive technology may herald a new era as regards our perception of the CVS and its diseases. Several of these themes were discussed at length in a meeting held by the Section of Comparative Medicine on 21 November 1984 which, as Professor A D Dayan (St Bartholomew's Hospital) explained in his introduction, had been arranged primarily to review some basic homeostatic mechanisms and their application in the validation of animal models for cardiovascu.ilar disease.
The wide variation in homeostatic control mechanisms in the CVS was illustrated by the comparative studies of Professor P J Butler (University of Birmingham) on changes in 02 supply in response to exercise in non-mammalian vertebrates (see Butler 1985) . In swimming trout, 02 delivery is promoted by increasing extraction from the blood and by increasing cardiac stroke volume rather than by tachycardia. By contrast, in flying pigeons, the skeletal muscle requirement for 02 is satisfied by a substantial increment in heart rate with only a modest change in the extraction rate from blood. Between these extremes in response is the interesting example of the green turtle which, like other reptiles and amphibians, has an incompletely-divided ventricle. The lungs are ventilated infrequently at rest and the pulmonary blood flow varies with response to ventilation; during exercise pulmonary perfusion rises to a constant level and the left and right sides of the heart may now be -functionally separated, presumably by laminar flow. The response by trained ducks to exercise depends on the circumstances. The classic head-diving response includes a reduced heart rate and selective peripheral vasoconstriction, so that 02 is conserved for use by the central nervous system and heart while the rest of ' Report of meeting of the Section of Comparative Medicine, 21 November 1984 . Accepted 15 February 1985 the body metabolizes anaerobically. In more recent studies of underwater swimming, bradycardia was not observed and the heart rate was increased before diving in order to augment 02 stores. It is concluded that metabolism is completely aerobic during normal feeding (diving) behaviour in aquatic birds.
In a review of the mechanisms of integration of the respiratory and cardiovascular control systems in mammals, Professor M de Burgh Daly (Royal Free Hospital Medical School, London) described the type of information that can be obtained about a cardiovascular reflex from studies on the selective stimulation of a receptor in controlled conditions. In fact, because several receptor populations with discrete reflex functions are usually affected simultaneously, the observed response pattern is determined by the sum total of the information reaching the CNS, which often includes respiratory inputs, e.g. alterations in central inspiratory neuronal activity, pulmonary stretch receptor activity and the arterial CO2 tension. This fundamental topic is still an active research area (Daly 1983) and several experimental systems were discussed. For example, stimulation of carotid body chemoreceptors in dogs at constant pulmonary ventilation and arterial blood pressure causes reflex bradycardia and peripheral vasoconstriction, whereas the response is converted to tachycardia and vasodilatation if pulmonary ventilation is allowed to increase. Evidence was presented that these types of integrative response are qualitatively similar in all mammals; any quantitative differences can be explained by the relative magnitude of inputs from the receptors, the degree of interaction in CNS autonomic pathways and the modification by respiratory mechanisms.
The conclusion that the control of the CVS is essentially similar in mammalsby comparison with the general diversity of response in non-mammalian vertebrateswas endorsed by Professor C J Dickinson (St Bartholomew's Hospital, London) in his characterization of models of hypertension. High blood pressure is found naturally only in tall animals, egregiously the giraffe, and sporadically in dogs and rats where it accompanies chronic pyelonephritis. Experimentally, hypertension can be induced by various methods, principally neurogenic, renal, adrenal regenerative (which may have no clinical equivalent) and iatrogenic (angiotensin, i) 1985 The Royal Society of Medicine 0141-0768/85/080687-04/$02.00/0 noradrenaline or aldosterone infusion). Neurogenic models can be subdivided according to the involvement of arterial baroreceptors, higher CNS functions, brainstem, spinal cord or autonomic efferents, and were discussed in detail, with Professor Dickinson mentioning a particular interest: the role of an impaired blood supply to the brainstem in essential hypertension. Selective breeding, usually in rats, has created other models of hypertension and these can also be assigned, according to origin, as mainly renal or mainly neurogenic (Okamoto strain). The latter is considered to be the model most similar to man and responds to those agents used therapeutically.
Thus, drugs can be used as pharmacological tools to evaluate the predictive ability of animal models and, in turn, experimental models are used to discover new compounds with clinical benefit. These aspects of cardiovascular research were amplified by Dr T C Hamilton (Beecham Pharmaceuticals Research Division, Harlow) in a presentation on the comparative pharmacology of blood pressure control. Although the blood-pressurelowering activities of propranolol (fl-blocker), clonidine (centrally-acting) and nifedipine (directly-acting vasodilator) were first detected in man, the agents are active in appropriate models and other clinically-useful drugs, such as prazosin (a-blocker), were discovered by testing in animals.
fl-blockers, are effective, for example, in a range of animal models, and although the dose-response varies considerably it is now appreciated that the greatest activity is achieved after adrenal demedullation (Buckingham & Hamilton 1979) . The apparently parodoxical effect of clonidinea vasoconstrictor-on blood pressure is explained by central stimulation of a2-receptors, and the hypertension which may develop on withdrawal can be reproduced in animal models. The directlyacting vasodilators are consistently active in the common models and the order of relative potencies reflects clinical findings; the antihypertensive effects are sometimes associated with reflex tachycardia in animals as in man, although this undesirable side effect is attenuated for the novel Beecham compound BRL 34915. The newest class of drugs, the angiotensin-converting enzyme inhibitors (captopril, enalapril) are -most active in those models with a high.renin status; in both spontaneously-hypertensive rats and in man the response to enalapril is potentiated by coadministering a diuretic. Although research using animal models of hypertension has contributed to the identification of new drugs, it should be appreciated that several types of model may be needed to ensure detection of all classes of agent. One approach is to use rats (spontaneously hypertensive) as a primary screen, with cats (renal model) as a secondary screen, and dosing both acutely and chronically. It is also possible to make some assessment of the merits of vasodilators, fl-blockers and angiotensin-converting enzyme inhibitors in subsequent work on volunteers.
The afternoon session began with Professor F J Macartney (Hospital for Sick Children, London) relating how the practice of paediatric cardiology has been transformed by the use of noninvasive, ultrasound techniques to replace cardiac catheterization and angiography. Examples were presented of the type of anatomical information acquired in a range of abnormalities, including hypertrophic cardiomyopathy, Type III glycogen storage disease (left ventricular hypertrophy), pulmonary atresia and rhabdomyoma of the intraventricular septum. It is also feasible to obtain physiological information by studying the change in frequency between the reflected and transmitted ultrasonic beam. Interpretation of the early studies was admitted to be ambiguous, but greater precision is now available from techniques such as range-gated Doppler scanning. It should be noted, however, that the use of ultrasound requires a compromise between depth and resolution, so that although the problem of the rapid motion of the heart has now been overcome, the production of high-resolution pictures of the adult heart is still difficult.
Atherosclerosis is a disorder of the CVS whose characterization and potential treatment would be greatly advanced by a noninvasive monitoring technique. Professor G A Gresham (Addenbrooke's Hospital, Cambridge) described how some of the conventional risk factors for atherosclerosis, e.g. hyperlipidaemia, hypertension and stress, can be reproduced experimentally in primates, birds and rabbits and may also account for the high incidence of the disease in zoo animals. It might be added that in view of the recent evidence linking heart rate and atherosclerosis (Beere et al. 1984) it would be interesting to establish if the phylogenetic variation in heart rate response to exercise, disclosed by Professor Butler, was correlated with the natural incidence of the disease. The traditional animal models are imperfect, for whilst the relatively simple fatty streak may be the equivalent of the primary lesion in man (that progresses to the fibrous plaque), the arterial wall usually remains well nourished by the vasa vasorum and the atheroma rarely predisposes to thrombosis. The possibility of therapy was discussed and Professor Gresham believed that early lesions could regress. Advanced lesions in the coronary arteries are, ostensibly, more resistant, but it is worth noting that recent clinical work shows that treatment of hyperlipidaemia at least prevents Journal ofthe Royal Society ofMedicine Volume 78 August 1985 689 their progression, and improves cardiac survival (Nikkila et al. 1984) . The nature of the atherosclerotic lesion depends on the type of artery involved, and there may be a problem in extrapolating from those changes in the aorta that are most commonly studied in animal models.
Consideration of the disparate nature of the disease is also relevant to the presentation of Dr R Finlayson (Wellcome Foundation) in which the rates for coronary mortality in the City of London during the last century were compared with the prevalence of aortic aneurysms and aortic atherosclerosis identified from autopsy records. Apart from the assumption that atherosclerosis in the aorta can be related to events in the coronary arteries, any historical survey of this type may be confounded by problems of changing diagnostic habits, incomplete records and a progressively ageing postmortem population. Accepting these limitations, Dr Finlayson suggested that the modern epidemic of coronary mortality started in the second decade of this century and the subsequent marked increase was not associated with a corresponding change in the severity of atherosclerosis. It is generally agreed, of course, that whilst atheroma may be central to the development of coronary heart disease, it is not a sufficient cause of acute myocardial infarction; other pathological eventsparticularly thrombosis, cardiac dysrhythmia and coronary spasmare the acute precipitating factors. Without specifying the mechanism, Dr Finlayson identified a risk factor that appears to have increased concomitantly with the rise in coronary death -the smoking of commercially-manufactured cigarettes.
It has been postulated that fibrin deposition may contribute to the development of atherosclerosis (Smith et al. 1979) . It is now certain that fibrin is a major constituent of the coronary thrombus. The potential for fibrinolytic agents in the therapy both of arterial and venous thrombosis was reviewed by Drs H Ferres and R J Dupe (Beecham Pharmaceuticals Research Division, Great Burgh). Dr Ferres explained how endogenous fibrinolysis might be impaired in thrombotic states. The pharmacological approach is to activate the pro-enzyme plasminogen within the thrombus so that production of the fibrindegrading enzyme plasmin occurs at the site where it is needed and systemic effects on haemostasis are minimized. Plasminogen activators have been administered only rarely to treat deep vein thrombosis, partly because of a perceived risk of bleeding in postoperative patients and partly because of problems of diagnosis. The use of fibrinolytics to treat myocardial infarction had also been controversial, but there is renewed confidence in the value of early restoration of coronary patency and salvage of heart muscle. Dr Ferres defined the requirements for the ideal fibrinolytic agent: these included delivery as a rapid bolus injection and maintenance of a circulating blood level as well as a selective action within the clot. The plasminogen activators available at presentstreptokinase and urokinaseare seen to have defects. Agents in development, notably the Beecham acylated streptokinase-plasminogen activator complexes (BRL 26921, BRL 33575), tissue-plasminogen activator and pro-urokinase, are considered to possess a degree of clot-specificity for different reasons, but it was emphasized that any greater selectivity is only relative and will depend on the clinical conditions and the dose used.
Dr Dupe delineated some of the principles supporting the animal models used to select the novel agents BRL 26921 and BRL 33575. As Professor Gresham had stated, thrombosis rarely occurs naturally in laboratory animals and, moreover, there is considerable species variation in the response of plasminogen to exogenous activators. The rabbit was used in primary screening but subsequent evaluation used the dog, in part because the fibrinolytic system was biochemically more relevant to man. In all models, activity was monitored by incorporating radiolabelled fibrin into the experimental thrombus and measuring the release of degradation products into the circulation. Venography was also used routinely in dogs, as in the clinic, to examine whether vessel patency was restored or whether, for example, rethrombosis occurred. Thrombi could also be aged so as to produce changes in the fibrin network in an attempt to mimic the range of clinical conditions encountered. The slowly-deacylating agent, BRL 33575, appeared to be the drug of choice for the older types of thrombus where sustained proteolytic attack was required; BRL 26921 gave a faster lytic attack on the thrombus in animal models and, clinically, was most useful for coronary occlusions (Green et al. 1985 ). Dr Dupe also described a new approach to the induction of both venous and arterial thrombosis. Low-intensity anodal stimulation to the endothelium was delivered with a modified balloon catheter, thus minimizing surgical intervention and so facilitating prophylactic studies.
In summary, the contributors to the meeting presented detailed information on many aspects of the regulation of the CVS in a range of animal species. It is clear that an understanding of the biochemistry and physiology of basic control mechanisms is necessary in order to evaluate the validity of animal models for human disease, and examples were presented of the ability of models of hypertension and thrombosis to identify new therapeutic agents. It has been comparatively difficult to ascertain the role of atherosclerosis in coronary heart disease, but it is to be hoped that progress will be accelerated by the development of new genetic models (Watanabe 1980 ) and by the same commitment to noninvasive monitoring techniques that has revolutionized other areas of cardiology.
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News from the President (No. 2)
As I write this my second message to Fellows and members for 1985, the great day has come at last and we have moved into our magnificent new building, the completion of which has been so long awaited. Frankly, I find it breathtaking. The facilities it provides for social, scientific and professional activities are quite outstanding and the quality of the rooms and furnishings in the new Domus Medica is far superior to that in many London hotels and certainly better than that which most London clubs can provide. The entrance hall, adorned by large numbers of portraits which the Society has owned for some years and which are now hung to their best advantage, is splendid, as is the conservatory, while the Merck Sharp & Dohme Room, the buttery and the restaurant are also exceptional and will offer Fellows the opportunity of having meals in delightful and congenial surroundings. I have no doubt that, with the quality of the new kitchens and other associated facilities, Mr Bowen and his staff will provide meals to match the beauty of the surroundings in which they will be served. I hope that many Fellows and members will soon avail themselves of the opportunity of trying out what is new on offer in these splendid new surroundings. Of course, we must recognize that our move into the new building will be followed by a period of disruption while the Society's original house is being refurbished, but the start on site by the contractors took place as planned on 7 May and we are hopeful that the full programme will have been completed by the end of January 1986. Well before then we shall be thinking of a date in the spring or summer of 1986 for a formal opening, and I shall keep Fellows and members fully informed about our plans. I am glad to say that satisfactory arrangements have been made, so far as one can judge, for all the Society and Section meetings and associated social events which are due to take place within the next academic year, at least until Easter 1986. I hope that members will be so impressed by the quality of the new facilities that the Society can now provide that they will accept this period of temporary disruption, especially to Library services, in anticipation of the quite superb facilities we shall have by the middle of next year.
In my last column (May JRSM, p 415) I referred to the serious financial position in which the Society finds itself, having accumulated a substantial deficit over the two years 1982/83 and 1983/84. Council, on the advice of the Scientific and Executive Committee and the Honorary Officers, have taken action to try to improve the situation, but I fear a moderate increase in subscriptions is inevitable in the 1985/86 session, though I am satisfied that all Fellows and members who have an opportunity of using the facilities in the new building will feel that this is wholly justified. Similarly, I believe that Fellows will find the JRSM more attractive in the new format which will be adopted in 1986. Of course, we must above all continue our drive to recruit new Fellows and members; anything that members can continue to do in this regard would be most helpful. We are continuing with our efforts to recruit Fellows through approaches to. specialty societies
